NCT02287428 2026-04-17
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
10 trialsNCT05064280 2026-04-16
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05317858 2026-04-16
LIMITLESS
InSightec
Phase 3 Recruiting
NCT04659811 2026-04-15
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
University of California, San Francisco
Phase 2 Active not recruiting
NCT02359565 2026-04-13
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03277638 2026-04-09
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
Case Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT07301268 2026-04-08
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Phase 2 Recruiting
NCT01822652 2026-04-06
GRAIN
Baylor College of Medicine
Phase 1 Active not recruiting
NCT06514898 2026-04-03
MATCHPOINT
University of Florida
Phase 1 Active not recruiting
NCT03449238 2026-03-30
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Weill Medical College of Cornell University
Phase 1/2 Recruiting